Rinath Jeselsohn

1 month ago | nature.com | R. C. Coombes |Simon Lord |Zahi Mitri |Carlo Palmieri |William Gradishar |Patrick Ward | +2 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row...

Oct 23, 2024 | nature.com | Alexandre Poirier |Anne-Marie N. Fortier |Nancy Lin |Morag Park |Michel Tremblay |Rinath Jeselsohn

AbstractRecurrent breast cancers often develop resistance to standard-of-care therapies. Identifying targetable factors contributing to cancer recurrence remains the rate-limiting step in improving long-term outcomes. In this study, we identify tumor cell-derived osteopontin as an autocrine and paracrine driver of tumor recurrence. Osteopontin promotes tumor cell proliferation, recruits macrophages, and synergizes with IL-4 to further polarize them into a pro-tumorigenic state.

Aug 10, 2024 | cancernetwork.com | Erika Hamilton |Rinath Jeselsohn |Sara A. Hurvitz |Dejan Juric |Hyo S Han |Melinda L. Telli | +8 more

BackgroundVepdegestrant (ARV-471) is an oral proteolysis-targeting chimeras (PROTAC) estrogen receptor (ER) degrader. In a phase 1/2 study (NCT04072952), vepdegestrant monotherapy had a favorable safety profile and encouraging clinical activity with robust ER degradation. The phase 1b cohort of this study is evaluating vepdegestrant plus the CDK4/6inhibitor palbociclib.

Aug 4, 2024 | cancernetwork.com | Sara A. Hurvitz |Anne F. Schott |Cynthia X. MA |Rita Nanda |George Zahrah |Natasha Hunter | +10 more

BackgroundVepdegestrant (ARV-471) is an oral proteolysis-targeting chimeric (PROTAC) estrogen receptor (ER) degrader with activity toward wild-type and mutant ER. The phase 2 expansion (VERITAC) of a phase 1/2 study tested 2 vepdegestrant doses (200 mg once daily and 500 mg once daily) in heavily pretreated patients with ER+/HER2-negative (HER2–) advanced breast cancer.

Dec 14, 2023 | nature.com | Paolo Tarantino |Ana C. Garrido-Castro |Brittany L. Bychkovsky |Lynette M. Sholl |Matthew Meyerson |Rinath Jeselsohn | +5 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-023-43324-w, published online 18 November 2023In this article, the author names Paolo Tarantino, Hersh Gupta, Melissa E. Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana C. Garrido-Castro, Romualdo Barroso-Sousa, Brittany L. Bychkovsky, Simona DiLascio, Lynette Sholl, Laura MacConaill, Neal Lindeman, Bruce E. Johnson, Matthew Meyerson, Rinath Jeselsohn, Xintao Qiu, Rong Li, Henry Long, Eric P.